<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552393</url>
  </required_header>
  <id_info>
    <org_study_id>NH19708</org_study_id>
    <secondary_id>2016-004779-39</secondary_id>
    <nct_id>NCT03552393</nct_id>
  </id_info>
  <brief_title>Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter Sudy to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of
      anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on
      dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin
      alfa, epoetin beta, or darbepoetin alfa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">October 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Haemoglobin (Hb) Concentration (Gram per Decilitre [g/dL])</measure>
    <time_frame>up to Week 21</time_frame>
    <description>Change in Hb concentration (g/dL) between the baseline and the evaluation period for each patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an average Hb concentration during the evaluation period within ± 1 g/dL of their baseline Hb or above, within or below the range of 10−12 g/dL</measure>
    <time_frame>Week 17 up to Week 21</time_frame>
    <description>Hb concentration during the evaluation period within ± 1 g/dL of their baseline Hb or above, within or below the range of 10−12 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mircera dose over time, including the change between the starting dose and the evaluation period</measure>
    <time_frame>Week 1 to Week 17</time_frame>
    <description>Change between the starting dose and the evaluation period will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events by Severity</measure>
    <time_frame>Up to Week 45</time_frame>
    <description>An adverse event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition), recurrence of an intermittent medical condition or any deterioration in a laboratory value or other clinical test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Up to Week 45</time_frame>
    <description>Change in systolic and diastolic blood pressure will be evaluated and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Up to Week 45</time_frame>
    <description>Change in pulse rate will be evaluated and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in targeted clinical laboratory test results</measure>
    <time_frame>Screening up to Week 45</time_frame>
    <description>Targeted clinical laboratory results will includes hematology, aspartate transaminase (AST), alanine transaminase (ALT), C-reactive protein, potassium, phosphorus, calcium, platelets, serum creatinine and iron parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of Mircera</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Mircera</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of Mircera</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; Post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of Mircera</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of Mircera</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
    <description>Bioavailability is defined as the rate and extent to which the administered drug reaches the systemic circulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Serum Concentration of Hb</measure>
    <time_frame>Pre-dose at Week 1, 9, 17; post-dose at Week 3 and Week 19 and additional sample will be taken between 24 hours and 5 Days at patient's convenience</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anemia</condition>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Mircera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mircera will be administered subcutaneously once every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mircera</intervention_name>
    <description>The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.</description>
    <arm_group_label>Mircera</arm_group_label>
    <other_name>Methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric participants 3 months to 17 years of age with clinically stable chronic
             renal anemia

          -  CKD with estimated glomerular filtration rate (eGFR) of &lt; 45 mL/min/1.73 m2
             (determined by the Bedside Schwartz formula) or dialysis treatment for at least 8
             weeks before the first dose of Mircera

          -  For participants on peritoneal dialysis (PD): a weekly Kt/V≥ 1.8

          -  For participants on HD: adequate HD, urea reduction ratio (URR) &gt; 65% or Kt/V &gt; 1.2
             for participants on HD three times per week.

        Participants with fewer than or more than three HD sessions per week should have a weekly
        Kt/V≥ 3.6.

          -  Baseline Hb concentration 10.0-12.0 g/dL determined from the mean of two Hb values
             measured at Visit 1 (Week -3) and Visit 2 (Week -1)

          -  Stable SC maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa
             with the same dosing interval for at least 6 weeks before the first dose of Mircera

          -  Stable dose of epoetin alfa, epoetin beta, or darbepoetin alfa treatment with no
             weekly dose change &gt; 25% (increase or decrease) for at least 4 weeks before the first
             dose of Mircera

          -  Adequate iron status defined as ferritin≥100 ng/mL or transferrin saturation (TSAT)≥
             20% (or percentage of hypochromic red cells &lt; 10%); mean of two values measured during
             screening.

        Exclusion Criteria:

          -  Overt gastrointestinal bleeding within 8 weeks before screening or during the
             screening period

          -  RBC transfusions within 8 weeks before screening or during the screening period

          -  Hemoglobinopathies (e.g., homozygous sickle-cell disease, thalassemia of all types)
             Hemolytic anemia, Active malignant disease

          -  PD subjects with an episode of peritonitis within the past 30 days prior to screening
             and/or during the screening period

          -  Uncontrolled or symptomatic inflammatory disease (e.g., systemic lupus erythematosus)

          -  Uncontrolled hypertension as assessed by the investigator

          -  Epileptic seizures within 3 months prior to screening and during the screening period

          -  Administration of any investigational drug within 4 weeks prior to screening or
             planned during the study

          -  Severe hyperparathyroidism (intact parathyroid hormone [PTH]≥ 1000 pg/mL or whole PTH≥
             500 pg/mL) or biopsy-proven bone marrow fibrosis

          -  Kidney transplant with use of immunosuppressive therapies known to exacerbate anemia

          -  Known hypersensitivity to recombinant human erythropoietin (EPO), polyethylene glycol,
             or any constituent of the study drug formulation

          -  Anti-EPO antibody (AEAB)-mediated pure red cell aplasia (PRCA) or history of AEAB
             mediated PRCA or positive AEAB test result in the absence of PRCA

          -  High likelihood of early withdrawal or interruption of the study (e.g., planned living
             donor kidney transplant within 5 months of study start)

          -  Planned elective surgery during the entire study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: NH19708 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham; Pediatric Nephrology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loma Linda University health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles; Pharmacy Department</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital; Nemour's Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Med; Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Childrens' Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children'S Mercy Hospital; Pediatric Nephrology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RWJBarnabas Health</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Carolina University; Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center; Pediatrics Dept.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Texas At Houston; Ped Neph &amp; Hypertension</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne De Flandre; Pediatrie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré; Nephrologie pediatrique</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gh Necker Enfants Malades; Nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Höpital Hautepierre; Pediatrie 1</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>KfH-Nierenzentrum fur Kinder und Jugendliche</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University; 1st Department of Pediatrics, Pediatric Nephrology Center</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ; Gyermekklinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica II De Marchi</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita; U.O. Autonoma di Nefrologia, Dialisi e Trapianto</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Di Padova; Dipartimento Di Pediatria U.O. Di Nefrologia Pediatrica, Dialisi e Trapianto</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vilnius University Children's Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadciśnienia Dzieci i Mlodziezy</name>
      <address>
        <city>Gdansk</city>
        <zip>80-294</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dziecięcy w Krakowie; Oddz.Nefrologii i Nadciśnienia Tętniczego/Stacja Dializ</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Centrum Zdrowia Matki Polki; Klinika Pediatrii i Immunologii i Nefrologii</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny dla Dzieci i Doroslych; Oddzial Kliniczny Pediatrii i Nefrologii</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny nr 1 im. prof. Szyszko; Oddz. Nefrologii Dzieciecej z Pododdziałem Dializoterapii</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Nefrologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Nefrologia Pediatrica</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

